A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Clinical trial NCT03584009 · TERMINATED

Trial details

NCT number: NCT03584009
Sponsor: Hoffmann-La Roche
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Start date: 2018-09-06
Primary completion: 2020-08-05
Enrollment: 103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.